Keros Therapeutics (KROS) Share-based Compensation (2019 - 2025)

Keros Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at -$17.4 million for Q3 2025.

• Quarterly Share-based Compensation fell 297.4% year-over-year to -$17.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $9.2 million (down 64.16% YoY) and the FY2024 annual result came in at $34.9 million, up 2506.28% from the prior year.
• Share-based Compensation was -$17.4 million for Q3 2025 at Keros Therapeutics, down from $8.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $15.4 million in Q4 2022 and bottomed at -$17.4 million in Q3 2025.
• A 5-year average of $4.2 million and a median of $8.1 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2021 — Share-based Compensation jumped 20683.33% — and 2025, when it tumbled 297.4%.
• Keros Therapeutics' Share-based Compensation stood at $3.3 million in 2021, then surged by 368.07% to $15.4 million in 2022, then slumped by 173.85% to -$11.4 million in 2023, then jumped by 180.77% to $9.2 million in 2024, then tumbled by 289.18% to -$17.4 million in 2025.
• Business Quant data shows KROS's Share-based Compensation at -$17.4 million in Q3 2025, $8.5 million in Q2 2025, and $8.9 million in Q1 2025.